{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"MTD is defined as the maximum dose at which less than 33% of participants experience a dose-limiting toxicity (defined as any events occurring within the first cycle of treatment (21 days) such as any death not clearly due to the underlying disease or extraneous causes).","groups":[{"description":"All Participants in Dose Escalation Dose Level 1, and Dose Level 2 administered LMB-100: Both Arms intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 and Tofacitinib orally twice daily on days 1-10 of each cycle, and LMB-100.","id":"OG000","title":"All Participants in Dose Escalation Dose Level 1, and Dose Level 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"First cycle of treatment (21 days)","title":"Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib","type":"PRIMARY","unitOfMeasure":"mcg/kg given days 4, 6, 8 every cycle"}